Comparison of Minimum Inhibitory Concentration (MIC) value of statin drugs: A Systematic Review
-
Published:2018-12-19
Issue:1
Volume:17
Page:4-19
-
ISSN:2211-3525
-
Container-title:Anti-Infective Agents
-
language:en
-
Short-container-title:AIA
Author:
Gupta Meenakshi1, Kumar Anoop1
Affiliation:
1. Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India
Abstract
Background:
Microbial infection and its resistance to clinically approved drugs create a huge
threat to human health. Emerging reports have indicated the potential of statin drugs in the treatment of
various types of microbial infections. However, it is still unclear, how much concentration of statin is
effective against microbial infections. In literature, Minimum Inhibitory Concentration (MIC) values of
statin drugs vary according to strain, species, and the type of statins. Thus, the main aim of the current
study is to compare the MIC values of various types of statins against various types of micro-organisms.
The data related to statin and microbial infection has been extracted from Pub Med (from
September 1
Methodology:
987 to October 2017). A total of 662 studies have been published from 1987 -2017 regarding
statin and microbial infections. After inclusion and exclusion criteria, finally, 28 studies have been
selected for comparative analysis of MIC values.
Results:
All the statin drugs have shown a significant effect on various types of microbial infections.
Among all the tested statin drugs, Simvastatin has lower MIC value in almost all types of microorganisms
as compared to other statin drugs. However, on S. pneumoniae and aspergillus, Fluvastatin has
the lowest MIC values as compared to Simvastatin. Atorvastatin was found to be the most potent
against almost all strains of gram-negative bacteria. However, Rosuvastatin and Pravastatin have high
MIC value against all types of microorganisms. Further, FICI value indicated the synergetic effect of
Simvastatin with Amphotericin B, Itraconazole, and Fluconazole against various strains of Cryptococcus.
Conclusion:
In conclusion, Simvastatin, Atorvastatin, and Fluvastatin could be developed as potential
antimicrobial agents. However, further studies are required to understand its complete safety and efficacy
profile..
Publisher
Bentham Science Publishers Ltd.
Subject
Infectious Diseases,Pharmacology
Reference32 articles.
1. Tabish SA, Syed N. Int J Sci Res, The future of humanity and microbes: Impact of emerging infectious diseases on global health and economies.,, 2015, 4,, 2427-2442, 2. . Geneva: Department of Health Statistics and Information
Systems, , WHO; G.WHO methods and data sources for global burden of
disease estimates, 2000-2011 3. Bannister RM, Wanderlay WC, Brew J. Treatment of Microbial Infections, Biocopea Limited, U.S. Patent Application 13/509, 2010 4. Caldwell JR, Cluff LE. JAMA, Adverse reactions to antimicrobial agents.,, 1974, 230,, 77-80, 5. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Cochrane Database Syst Rev, Statins for the primary prevention of cardiovascular disease.,, 2011, 1,, 77-,10.1002/14651858.CD004816.pub5
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|